×
GSK Net Income 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GSK net income for the twelve months ending June 30, 2024 was
$5.093B
, a
73.01% decline
year-over-year.
GSK annual net income for 2023 was
$6.13B
, a
66.86% decline
from 2022.
GSK annual net income for 2022 was
$18.499B
, a
206.79% increase
from 2021.
GSK annual net income for 2021 was
$6.03B
, a
18.31% decline
from 2020.
View More
GSK Net Income 2010-2024 | GSK
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
GSK annual net income for 2023 was
$6.13B
, a
66.86% decline
from 2022.
GSK annual net income for 2022 was
$18.499B
, a
206.79% increase
from 2021.
GSK annual net income for 2021 was
$6.03B
, a
18.31% decline
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.8B
Regeneron Pharmaceuticals (REGN)
$126.4B
Vertex Pharmaceuticals (VRTX)
$124.2B
Gilead Sciences (GILD)
$103.4B
Bristol Myers Squibb (BMY)
$100.3B
CSL (CSLLY)
$97.4B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Argenex SE (ARGX)
$31.2B
BioNTech SE (BNTX)
$29.7B
Biogen (BIIB)
$28.9B
Moderna (MRNA)
$27.7B
Illumina (ILMN)
$20.7B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.5B
BioMarin Pharmaceutical (BMRN)
$13.4B
Vaxcyte (PCVX)
$13B
Incyte (INCY)
$12.8B
Insmed (INSM)
$12.6B
Exact Sciences (EXAS)
$12.6B
Sarepta Therapeutics (SRPT)
$12B
Bio-Techne Corp (TECH)
$11.9B
QIAGEN (QGEN)
$10.4B
Legend Biotech (LEGN)
$9.3B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.5B
Intra-Cellular Therapies (ITCI)
$7.9B
Exelixis (EXEL)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B
Repligen (RGEN)
$7.6B